First author on several peer-reviewed papers, Mark Aspinall-O’Dea is an Associated Director in Advanced Modalities at Charles River. Mark's scientific experience includes 10 years of postdoctoral research in clinical and academic settings, and more than 10 years of commercial experience in the biopharmaceutical field. Mark currently leads a large research team focused on the Retrogenix® cell microarray platform and future technology developments.
WEBINAR REPLAY: Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening
Join us for a case-based webinar showcasing how the Retrogenix® platform empowers smarter, earlier decisions across biologic formats. You’ll also learn how this platform, recently accepted into the FDA’s ISTAND Pilot Program, aligns with evolving regulatory support for NAMs and the shift toward reduced animal use.
View Replay